Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on September 26, 2013. The filing covers corporate governance events, including the termination of an advisory agreement, the resignation of two directors, the election of a new director, and the results of a stockholder consent solicitation regarding equity compensation plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan approvals rather than financial performance.
Material Changes
- Advisory Agreement Termination: The Advisory Agreement with Robert Kammer, Chairman of the Board, was terminated effective September 30, 2013. Dr. Kammer will continue to serve as Chairman.
- Director Resignations: Paul Finnegan resigned effective October 1, 2013, and Jeffrey Abrams resigned effective September 29, 2013. Both cited personal reasons and stated no disagreement with the Company. Dr. Abrams will continue as a consultant.
- New Director Election: Peter Kenny was elected to the Board effective October 2, 2013, and appointed to the Audit and Compensation Committees (serving as Chair of the latter). Gus Bassani was appointed to the Audit Committee.
- Equity Plan Approval: Stockholders approved increasing the share pool for the 2007 Incentive Stock and Awards Plan from 2,400,000 to 5,000,000 shares and raising the individual annual grant limit for performance-based compensation from 600,000 to 1,250,000 shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. The document notes that the resignations of directors Finnegan and Abrams were not due to any disagreement with the Company. Mr. Kenny received 8,947 restricted stock units (RSUs) vesting in full on the 13-month anniversary of the grant date.
Investor Verification Checklist
- Verify the impact of the increased equity pool (5,000,000 shares) on potential future dilution.
- Confirm the continued role of Jeffrey Abrams as a consultant and his access to proprietary information.
- Review the specific terms of the new director compensation and the vesting schedule for Peter Kenny's RSUs.
- Check subsequent filings for any changes in the Board composition or executive leadership following these transitions.